

MARKET REPORT



Thalassemia - Pipeline Review, H2 2017

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Thalassemia - Pipeline Review, H2 2017

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** bioportfolio97@gmail.com

Thalassemia - Pipeline Review, H2 2017

Thalassemia - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thalassemia - Pipeline Review, H2 2017, provides an overview of the Thalassemia (Hematological Disorders) pipeline landscape.

Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thalassemia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Thalassemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thalassemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thalassemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 8, 15 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 2 and 1 molecules, respectively.

Thalassemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Thalassemia (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Thalassemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Thalassemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Thalassemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Thalassemia (Hematological Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Thalassemia (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Thalassemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Additional Details

Publisher : Global Markets Direct

Reference : GMDHC9638IDB

Number of Pages : 141

Report Format : PDF

Publisher Information :

Global Markets Direct
The home of leading edge research and analysis

BioPortfolio
Life Science Healthcare and Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

Table Of Contents for Thalassemia - Pipeline Review, H2 2017

- Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Thalassemia - Overview 6
Thalassemia - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 11
Products under Development by Companies 12
Products under Development by Universities/Institutes 14
Thalassemia - Therapeutics Assessment 15
Assessment by Target 15
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Thalassemia - Companies Involved in Therapeutics Development 23
Acceleron Pharma Inc 23
Agiros Pharmaceuticals Inc 23
Alnylam Pharmaceuticals Inc 24
bluebird bio Inc 24
Cadila Healthcare Ltd 25
Calimmune Inc 25
CRISPR Therapeutics 26
Editas Medicine Inc 26
Errant Gene Therapeutics LLC 27
Gamida Cell Ltd 27
Gilead Sciences Inc 28
Incyte Corp 28
lonis Pharmaceuticals Inc 29
IRBM Science Park SpA 29
Kiadis Pharma NV 30
La Jolla Pharmaceutical Company 30
Merck & Co Inc 31
Protagonist Therapeutics Inc 31
Sangamo Therapeutics Inc 32
Thalassemia - Drug Profiles 33
(decitabine + tetrahydrouridine) - Drug Profile 33
ACY-957 - Drug Profile 34
AG-348 - Drug Profile 37
ALN-TMP - Drug Profile 42
ambrisentan - Drug Profile 44
ATIR-201 - Drug Profile 47
BB-305 - Drug Profile 48
benserazide - Drug Profile 57
CAL-H - Drug Profile 59
CordIn - Drug Profile 60
Drugs to Chelate Iron for Bone Degeneration, Postmenopausal Osteoporosis and Thalassemia - Drug Profile 61
Gene Therapy for Sickle Cell Disease and Thalassemia - Drug Profile 62
Gene Therapy to Activate IGF2BP1 for Sickle Cell Disease and Thalassemia - Drug Profile 63
GSK-2696277 - Drug Profile 64
IMR-687 - Drug Profile 65
IONISTMPRSS-6LRx - Drug Profile 66
LJPC-401 - Drug Profile 67
luspatercept - Drug Profile 69
M-009 - Drug Profile 78
M-012 - Drug Profile 79
NiCord - Drug Profile 81
PEG-EPO - Drug Profile 85
PHBB-101 - Drug Profile 86
PTG-300 - Drug Profile 87
RCY-1497 - Drug Profile 88
RNAi Gene Therapy for Sickle Cell Disease and Beta Thalassemia - Drug Profile 89
ruxolitinib phosphate - Drug Profile 90
SCD-101 - Drug Profile 105
sirolimus - Drug Profile 106
Small Molecule to Inhibit Histone Deacetylase 1 for Beta Thalassemia - Drug Profile 107
Small Molecules to Inhibit PRMT5 for Haemoglobinopathies and Solid Tumours - Drug Profile 108
sotatercept - Drug Profile 109
ST-400 - Drug Profile 114
Stem Cell Therapy for Beta Thalassemia and Sickle Cell Disease - Drug Profile 116
Stem Cell Therapy for Beta Thalassemia and Sickle Cell Disease - Drug Profile 117
Stem Cell Therapy to Activate Hemoglobin Beta for Beta-Thalassemia - Drug Profile 119
Thalagen - Drug Profile 120
Thalassemia - Dormant Projects 121
Thalassemia - Product Development Milestones 122
Featured News & Press Releases 122
Appendix 137
Methodology 137
Coverage 137
Secondary Research 137
Primary Research 137
Expert Panel Validation 137
Contact Us 137
Disclaimer 138

How to Buy...

Thalassemia - Pipeline Review, H2 2017

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/120506>

Option 2 - Request a Proforma Invoice

Fill in the details below, and **Scan** this page **and email** it to us at bioportfolio97@gmail.com We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$1700** | Single User Price
- \$3400** | Site License Price
- \$5100** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.